Therapeutic Drug Monitoring of Sputum Voriconazole in Pulmonary Aspergillosis
Voriconazole is one of the most used antifungal azoles against pulmonary aspergillosis. Therapeutic drug monitoring (TDM) of the voriconazole concentration in plasma is recommended in clinical practice guidelines to prevent treatment failure and toxicity. The aim of this study was to evaluate the fe...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/14/8/1598 |
| _version_ | 1797442781467115520 |
|---|---|
| author | Sacha Sarfati Julien Wils Timothée Lambert Céline Mory Laurent Imbert Gilles Gargala Hélène Morisse-Pradier Fabien Lamoureux |
| author_facet | Sacha Sarfati Julien Wils Timothée Lambert Céline Mory Laurent Imbert Gilles Gargala Hélène Morisse-Pradier Fabien Lamoureux |
| author_sort | Sacha Sarfati |
| collection | DOAJ |
| description | Voriconazole is one of the most used antifungal azoles against pulmonary aspergillosis. Therapeutic drug monitoring (TDM) of the voriconazole concentration in plasma is recommended in clinical practice guidelines to prevent treatment failure and toxicity. The aim of this study was to evaluate the feasibility and utility of TDM of the voriconazole concentration in the sputum of patients treated for pulmonary aspergillosis. Fifty sputum and 31 plasma samples were analysed with high-performance tandem mass spectrometry (HPLC-MS/MS) in 24 patients included in the study. The voriconazole concentration was simultaneously assessed in the plasma and sputum in 22 samples. The correlation between the sputum and plasma levels was estimated with a univariate linear regression model, and the observed R<sup>2</sup> was 0.86. We determined the following equation, C<sub>sputum</sub> = 0.45 (C<sub>plasma</sub>) + 0.21, which could predict the voriconazole concentration in plasma from sputum. TDM of the voriconazole concentration in sputum is an easy, non-invasive and accurate method with which to evaluate voriconazole exposure in patients with pulmonary aspergillosis. |
| first_indexed | 2024-03-09T12:47:04Z |
| format | Article |
| id | doaj.art-90fdaaa81ade4f5a8dc30e7cce3c7068 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-09T12:47:04Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-90fdaaa81ade4f5a8dc30e7cce3c70682023-11-30T22:11:16ZengMDPI AGPharmaceutics1999-49232022-07-01148159810.3390/pharmaceutics14081598Therapeutic Drug Monitoring of Sputum Voriconazole in Pulmonary AspergillosisSacha Sarfati0Julien Wils1Timothée Lambert2Céline Mory3Laurent Imbert4Gilles Gargala5Hélène Morisse-Pradier6Fabien Lamoureux7UNIROUEN, INSERM U1096, CHU Rouen, Department of Pharmacology, Normandie University, F-76000 Rouen, FranceUNIROUEN, INSERM U1096, CHU Rouen, Department of Pharmacology, Normandie University, F-76000 Rouen, FranceDepartment of Pneumology, CHU Rouen, F-76000 Rouen, FranceUNIROUEN, INSERM U1096, CHU Rouen, Department of Pharmacology, Normandie University, F-76000 Rouen, FranceUNIROUEN, INSERM U1096, CHU Rouen, Department of Pharmacology, Normandie University, F-76000 Rouen, FranceLaboratory of Parasitology-Mycology, EA7510 Rouen University Hospital, F-76000 Rouen, FranceDepartment of Pneumology, CHU Rouen, F-76000 Rouen, FranceUNIROUEN, INSERM U1096, CHU Rouen, Department of Pharmacology, Normandie University, F-76000 Rouen, FranceVoriconazole is one of the most used antifungal azoles against pulmonary aspergillosis. Therapeutic drug monitoring (TDM) of the voriconazole concentration in plasma is recommended in clinical practice guidelines to prevent treatment failure and toxicity. The aim of this study was to evaluate the feasibility and utility of TDM of the voriconazole concentration in the sputum of patients treated for pulmonary aspergillosis. Fifty sputum and 31 plasma samples were analysed with high-performance tandem mass spectrometry (HPLC-MS/MS) in 24 patients included in the study. The voriconazole concentration was simultaneously assessed in the plasma and sputum in 22 samples. The correlation between the sputum and plasma levels was estimated with a univariate linear regression model, and the observed R<sup>2</sup> was 0.86. We determined the following equation, C<sub>sputum</sub> = 0.45 (C<sub>plasma</sub>) + 0.21, which could predict the voriconazole concentration in plasma from sputum. TDM of the voriconazole concentration in sputum is an easy, non-invasive and accurate method with which to evaluate voriconazole exposure in patients with pulmonary aspergillosis.https://www.mdpi.com/1999-4923/14/8/1598therapeutic drug monitoringvoriconazolesputumtrough concentrationpulmonary aspergillosis |
| spellingShingle | Sacha Sarfati Julien Wils Timothée Lambert Céline Mory Laurent Imbert Gilles Gargala Hélène Morisse-Pradier Fabien Lamoureux Therapeutic Drug Monitoring of Sputum Voriconazole in Pulmonary Aspergillosis Pharmaceutics therapeutic drug monitoring voriconazole sputum trough concentration pulmonary aspergillosis |
| title | Therapeutic Drug Monitoring of Sputum Voriconazole in Pulmonary Aspergillosis |
| title_full | Therapeutic Drug Monitoring of Sputum Voriconazole in Pulmonary Aspergillosis |
| title_fullStr | Therapeutic Drug Monitoring of Sputum Voriconazole in Pulmonary Aspergillosis |
| title_full_unstemmed | Therapeutic Drug Monitoring of Sputum Voriconazole in Pulmonary Aspergillosis |
| title_short | Therapeutic Drug Monitoring of Sputum Voriconazole in Pulmonary Aspergillosis |
| title_sort | therapeutic drug monitoring of sputum voriconazole in pulmonary aspergillosis |
| topic | therapeutic drug monitoring voriconazole sputum trough concentration pulmonary aspergillosis |
| url | https://www.mdpi.com/1999-4923/14/8/1598 |
| work_keys_str_mv | AT sachasarfati therapeuticdrugmonitoringofsputumvoriconazoleinpulmonaryaspergillosis AT julienwils therapeuticdrugmonitoringofsputumvoriconazoleinpulmonaryaspergillosis AT timotheelambert therapeuticdrugmonitoringofsputumvoriconazoleinpulmonaryaspergillosis AT celinemory therapeuticdrugmonitoringofsputumvoriconazoleinpulmonaryaspergillosis AT laurentimbert therapeuticdrugmonitoringofsputumvoriconazoleinpulmonaryaspergillosis AT gillesgargala therapeuticdrugmonitoringofsputumvoriconazoleinpulmonaryaspergillosis AT helenemorissepradier therapeuticdrugmonitoringofsputumvoriconazoleinpulmonaryaspergillosis AT fabienlamoureux therapeuticdrugmonitoringofsputumvoriconazoleinpulmonaryaspergillosis |